William Blair analyst Myles Minter has maintained their bullish stance on ARGX stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Myles Minter has given his Buy rating due to a combination of factors surrounding Argenx Se’s stock. Despite recent volatility in Argenx shares following an FDA safety report, Minter views the situation as a buying opportunity. The report highlighted potential safety concerns with Vyvgart Hytrulo, but these are not new findings, and Argenx is proactively addressing them through clinician education and ongoing studies.
Furthermore, Minter points out that the real-world data shows a significantly lower rate of disease worsening in CIDP patients treated with Vyvgart Hytrulo compared to earlier reports. This, combined with the anticipated results from a Phase IV switch study, suggests that the risks are being effectively managed. Minter believes that as more clinical data emerges and clinician familiarity with the treatment increases, the stock’s potential will be further realized.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $804.00 price target.